Securian Asset Management Inc. Sells 341 Shares of Hologic, Inc. $HOLX

Securian Asset Management Inc. trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX) by 2.9% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 11,544 shares of the medical equipment provider’s stock after selling 341 shares during the quarter. Securian Asset Management Inc.’s holdings in Hologic were worth $752,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of HOLX. Chung Wu Investment Group LLC purchased a new position in shares of Hologic during the second quarter valued at approximately $26,000. Zions Bancorporation National Association UT purchased a new stake in Hologic in the first quarter worth approximately $34,000. Cromwell Holdings LLC grew its position in Hologic by 307.0% in the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 436 shares during the period. Allworth Financial LP raised its stake in Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 216 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Hologic during the 1st quarter valued at $42,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insiders Place Their Bets

In other news, Director Christiana Stamoulis sold 7,402 shares of the firm’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the completion of the sale, the director directly owned 47,336 shares of the company’s stock, valued at $3,458,841.52. This trade represents a 13.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the transaction, the chief executive officer directly owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. The trade was a 10.08% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.88% of the stock is owned by corporate insiders.

Hologic Stock Performance

NASDAQ:HOLX opened at $73.99 on Friday. The stock has a 50-day moving average price of $67.65 and a 200 day moving average price of $63.95. The stock has a market capitalization of $16.46 billion, a P/E ratio of 30.70, a P/E/G ratio of 2.54 and a beta of 0.63. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.39. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping the consensus estimate of $1.05 by $0.03. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HOLX has been the topic of several research reports. Evercore ISI set a $78.00 target price on Hologic and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Morgan Stanley raised their price objective on shares of Hologic from $65.00 to $69.00 and gave the stock an “equal weight” rating in a report on Thursday, July 31st. JPMorgan Chase & Co. restated a “neutral” rating and set a $78.00 target price on shares of Hologic in a research report on Wednesday. Mizuho downgraded shares of Hologic from an “outperform” rating to a “neutral” rating and increased their price target for the stock from $70.00 to $78.00 in a research report on Thursday. Finally, Raymond James Financial downgraded shares of Hologic from a “moderate buy” rating to a “hold” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and thirteen have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $79.23.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.